Latest news with #Merck
Yahoo
4 hours ago
- Business
- Yahoo
The 5 Most Interesting Analyst Questions From Merck's Q1 Earnings Call
Merck's first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% year-over-year revenue decline. Management identified continued strength in the oncology portfolio, especially KEYTRUDA and Welireg, alongside growth from new product launches like WinRevair and Cafaxib, as pivotal to performance. CEO Rob Davis cited 'increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline.' Merck also managed through significant declines in Gardasil sales in China, emphasizing that underlying global demand outside China remained robust. Is now the time to buy MRK? Find out in our full research report (it's free). Revenue: $15.53 billion vs analyst estimates of $15.29 billion (1.6% year-on-year decline, 1.6% beat) Adjusted EPS: $2.22 vs analyst estimates of $2.14 (3.8% beat) Adjusted EBITDA: $7.72 billion vs analyst estimates of $6.88 billion (49.7% margin, 12.2% beat) The company reconfirmed its revenue guidance for the full year of $64.85 billion at the midpoint Operating Margin: 37.8%, up from 35.7% in the same quarter last year Constant Currency Revenue rose 1% year on year (12% in the same quarter last year) Market Capitalization: $199.1 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Geoff Meacham (Citi): Asked how Merck plans to offset tariff headwinds. CEO Rob Davis explained supply chain restructuring and inventory management, emphasizing moves to 'U.S. for U.S.' manufacturing over price increases. Tim Anderson (Bank of America): Inquired about providing long-term guidance beyond KEYTRUDA's patent expiry. Davis reiterated confidence in the pipeline's potential but signaled no immediate plans for detailed long-term projections. Luisa Hector (Berenberg): Questioned the impact of FDA and HHS changes on vaccine approvals. Dr. Dean Li stated that near-term regulatory timelines remain on track, with no delays observed despite agency personnel transitions. Steve Scala (TD Cowen): Sought clarification on Gardasil's global growth outlook and long-term targets. CFO Caroline Litchfield noted the end of Japan's catch-up program and ongoing China headwinds, confirming the previous $11 billion Gardasil target has been withdrawn. Akash Tewari (Jefferies): Asked about the severity and impact of potential new tariffs. Davis declined to speculate on tariff rates but stressed Merck's preparedness through operational and manufacturing adjustments. In the coming quarters, the StockStory team will watch for (1) key data releases from late-phase clinical trials, especially in oncology and cardiovascular programs, (2) the impact of supply chain moves and tariff mitigation on cost structure, and (3) trends in Gardasil and other vaccine uptake outside China. Developments around regulatory filings and ACIP recommendations for vaccines will also be important markers to assess execution and pipeline momentum. Merck currently trades at $79.48, in line with $78.70 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Malaysian Reserve
21 hours ago
- Business
- Malaysian Reserve
Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline
The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increasing clinical trial activity are propelling the development of DLL3-targeted candidates. Growing interest from biopharma companies and strategic collaborations are also accelerating the DLL3-targeted therapies market expansion. LAS VEGAS, June 19, 2025 /PRNewswire/ — DelveInsight's Delta-like Ligand 3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging delta-like ligand 3 targeted therapies, market share of individual therapies, and current and forecasted delta-like ligand 3 targeted therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Delta-like Ligand 3 Targeted Therapies Market Report As per DelveInsight's analysis, the total market size of delta-like ligand 3 targeted therapies in the 7MM is expected to surge significantly by 2034. The approval of the first DLL3-targeted Bispecific T-cell Engager therapy, IMDELLTRA, by the US Food and Drug Administration (FDA) in May 2024 marked a pivotal moment for patients battling Extensive-stage small-cell lung Cancer (ES-SCLC). Leading delta-like ligand 3 targeted therapies companies, such as Phanes Therapeutics, Merck, Daiichi Sankyo, Legend Biotech, Novartis, Abdera Therapeutics, Boehringer Ingelheim, Chugai Pharmaceutical, Roche, Molecular Partners, Orano Med, Zai Lab, Allogene Therapeutics, and others, are developing novel delta-like ligand 3 targeted therapies that can be available in the delta-like ligand 3 targeted therapies market in the coming years. Some of the key delta-like ligand 3 targeted therapies in the pipeline include Peluntamig (PT217), MK-6070/DS3280, LB2102/ DLL3-targeted CAR Ts, 225Ac-ABD147, Obrixtamig (BI 764532), ALPS12/RG6524, MP0712, ZL-1310, ALL-213, and others. In February 2025, Phanes Therapeutics announced that the first patient was dosed in the clinical study of peluntamig (PT217) in combination with chemotherapy. In September 2024, Abdera Therapeutics announced that the US FDA granted ODD to ABD-147 for the treatment of NEC. In August 2024, Daiichi Sankyo and Merck expanded their existing global co-development and co-commercialization agreement for Merck's MK-6070 for the treatment of SCLC. Discover which indication is expected to grab the major delta-like ligand 3 targeted therapies market share @ Delta-like Ligand 3 Targeted Therapies Market Report Delta-like Ligand 3 Targeted Therapies Market Dynamics The delta-like ligand 3 targeted therapies market is emerging as a dynamic and promising area in oncology, particularly for hard-to-treat cancers like SCLC and other neuroendocrine tumors. With a growing understanding of its role in tumorigenesis, drug developers have shifted focus toward exploiting this target through various modalities, including ADCs, BiTEs, and CAR-T cell therapies. The FDA approval of tarlatamab (IMDELLTRA), a DLL3-targeted BiTE, has catalyzed commercial and clinical interest in this space. The competitive landscape is rapidly evolving, driven by both established pharmaceutical players and biotech innovators. Several companies are advancing DLL3-targeted assets through clinical pipelines, highlighting the growing investment and belief in the target's therapeutic value. Tarlatamab, in particular, has set a precedent by demonstrating durable responses in patients with extensive-stage SCLC who have limited treatment options after frontline chemotherapy. Its clinical success has validated DLL3 as a viable target and opened the door for additional programs in earlier lines of therapy and combination regimens. However, the DLL3-targeted therapy market faces challenges that could shape its trajectory. The heterogeneity of DLL3 expression among patient populations, potential for resistance mechanisms, and safety concerns, especially cytokine release syndrome (CRS) in immune-engaging therapies, are critical issues under active investigation. Additionally, biomarker-based patient selection strategies are essential to optimize efficacy, which may limit the addressable population unless companion diagnostics evolve in parallel. Market dynamics are also influenced by the broader shift toward personalized and immune-based treatments. The rise of bispecific and cell-based platforms enhances the flexibility in targeting DLL3, but also introduces manufacturing and logistical hurdles. As such, scalability, cost-effectiveness, and global accessibility will be important considerations in the commercial rollout. Reimbursement strategies and payer acceptance will further impact uptake, especially given the premium pricing associated with novel biologics. Looking ahead, the DLL3-targeted therapies market is poised for expansion beyond SCLC. Preliminary studies are exploring DLL3 expression in other neuroendocrine carcinomas, prostate cancer, and some pediatric tumors. This potential for label expansion, coupled with advancing drug formats and supportive regulatory pathways, indicates a robust growth trajectory. As the clinical pipeline matures and real-world data accumulate, DLL3-targeted approaches are expected to play an increasingly integral role in the precision oncology landscape. Delta-like Ligand 3 Targeted Therapies Treatment Market DLL3-targeted therapies are emerging as a promising new approach in the treatment of small-cell lung cancer and neuroendocrine carcinomas, bringing renewed optimism for patients with these aggressive cancers. A major breakthrough came in May 2024, when the US FDA approved IMDELLTRA, the first bispecific T-cell engager therapy targeting DLL3. Developed by Amgen, this first-in-class immunotherapy is designed to bind DLL3 on tumor cells and CD3 on T cells, triggering a T-cell–mediated attack on DLL3-expressing cancer cells through the formation of a cytolytic synapse. The approval and subsequent launch of IMDELLTRA have been widely recognized as a significant advancement in DLL3-focused treatments, generating approximately USD 115 million in US sales in 2024. This therapy offers a game-changing option for patients with previously treated Extensive-stage SCLC, showing durable responses. As the second FDA-approved BiTE molecule from Amgen, IMDELLTRA underscores the company's commitment to tackling hard-to-treat cancers. For patients urgently needing new therapeutic solutions, this approval delivers a much-needed and long-awaited source of hope. Learn more about the FDA-approved delta-like ligand 3 targeted therapies @ Approved Delta-like Ligand 3 Targeted Therapies Key Emerging Delta-like Ligand 3 Targeted Therapies and Companies The current pipeline is dominated with early-stage DLL-3 targeted therapies like peluntamig (Phanes Therapeutics), MK-6070/ HPN328-4001/ DS3280 (Merck / Daiichi Sankyo), LB2102/ DLL3-targeted CAR-Ts (Legend Biotech and Novartis), 225Ac-ABD147 (Abdera Therapeutics), BI 764532 (Boehringer Ingelheim), ALPS12/ RG6524 (Chugai Pharmaceutical and Roche), ZL-1310 (Zai Lab), and others. Peluntamig (PT217) is a first-in-class, native IgG-like bispecific antibody designed to target both DLL3 and CD47. It is being developed for the treatment of SCLC and neuroendocrine carcinomas, including neuroendocrine prostate cancer (NEPC). The FDA has awarded peluntamig two Orphan Drug Designations (ODDs) for SCLC and NEC, along with two Fast Track Designations (FTDs): one for extensive-stage SCLC that has progressed following platinum-based chemotherapy (with or without checkpoint inhibitors), and another for metastatic de novo or treatment-emergent NEPC. The therapy is currently undergoing evaluation in the Phase I/II SKYBRIDGE trial (NCT05652686) for SCLC and NEC. MK-6070 is an experimental tri-specific T-cell engager targeting DLL3, under Phase I/II clinical investigation. It is being tested as a standalone therapy in patients with advanced DLL3-expressing tumors and in combination with atezolizumab for certain cases of SCLC. The FDA granted MK-6070 Orphan Drug Designation for SCLC in March 2022. In March 2024, Merck finalized its acquisition of Harpoon Therapeutics, the original developer. In August 2024, Daiichi Sankyo and Merck expanded their global partnership to include MK-6070 under their co-development and co-commercialization agreement for DXd antibody-drug conjugates. Merck retains exclusive rights in Japan and will handle all manufacturing and supply responsibilities for MK-6070. The two companies also plan to explore the use of MK-6070 in combination with ifinatamab deruxtecan (I-DXd) for SCLC, along with other potential combination strategies. The anticipated launch of these emerging therapies is poised to transform the delta-like ligand 3 targeted therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the delta-like ligand 3 targeted therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about delta-like ligand 3 targeted therapies clinical trials, visit @ Delta-like Ligand 3 Targeted Therapies Treatment Delta-like Ligand 3 Targeted Therapies Overview Delta-like ligand 3 (DLL3) targeted therapies is an unconventional ligand within the Notch signaling pathway that, when overexpressed, supports the growth, migration, and invasiveness of small cell lung cancer (SCLC) cells. It also contributes to the development of metastatic and therapy-resistant traits in neuroendocrine carcinomas (NECs), enhancing both tumor cell proliferation and resistance to platinum-based chemotherapy. In normal cells, DLL3 expression is minimal and confined to the Golgi apparatus and cytoplasmic vesicles. This specific intracellular localization is regulated by its transmembrane domain and nearby protein sequences, which serve as retention signals. In contrast, SCLC cells exhibit high levels of DLL3 that are abnormally localized to the cell surface, a characteristic observed in up to 85% of human SCLC cases. While the mechanisms behind this overexpression and altered trafficking are not fully understood, DLL3's distinct expression pattern positions it as a promising biomarker and therapeutic target in SCLC. Beyond SCLC, DLL3 is also widely expressed in various NECs, including certain molecular subtypes of pulmonary large cell NEC (LCNEC) and NECs originating from the gastroenteropancreatic tract, bladder, prostate, and cervix. In these tumors, elevated DLL3 expression correlates with more advanced disease and poorer overall survival, suggesting a strong association between high DLL3 levels and unfavorable clinical outcomes. Delta-like Ligand 3 Targeted Therapies Epidemiology Segmentation The delta-like ligand 3 targeted therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for DLL3-targeted Therapies Total Eligible Patient Pool in Selected Indications for DLL3-targeted Therapies Total Treated Cases in Selected Indications for DLL3-targeted Therapies Delta-like Ligand 3 Targeted Therapies Report Metrics Details Study Period 2020–2034 Delta-like Ligand 3 Targeted Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Delta-like Ligand 3 Targeted Therapies Companies Phanes Therapeutics, Merck, Daiichi Sankyo, Legend Biotech, Novartis, Abdera Therapeutics, Boehringer Ingelheim, Chugai Pharmaceutical, Roche, Molecular Partners, Orano Med, Zai Lab, Allogene Therapeutics, Amgen, and others Key Delta-like Ligand 3 Targeted Therapies Peluntamig (PT217), MK-6070/DS3280, LB2102/ DLL3-targeted CAR Ts, 225Ac-ABD147, Obrixtamig (BI 764532), ALPS12/RG6524, MP0712, ZL-1310, ALL-213, IMDELLTRA, and others Scope of the Delta-like Ligand 3 Targeted Therapies Market Report Delta-like Ligand 3 Targeted Therapies Therapeutic Assessment: Delta-like Ligand 3 Targeted Therapies current marketed and emerging therapies Delta-like Ligand 3 Targeted Therapies Market Dynamics: Conjoint Analysis of Emerging Delta-like Ligand 3 Targeted Therapies Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Delta-like Ligand 3 Targeted Therapies Market Access and Reimbursement Discover more about delta-like ligand 3 targeted therapies in development @ Delta-like Ligand 3 Targeted Therapies Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Market Forecast Methodology 6. Delta-like Ligand 3 Targeted Therapies Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2034 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2034 7. Delta-like Ligand 3 (DLL3)-targeted Therapies: Background and Overview 7.1. Introduction 7.2. The Potential of Delta-like Ligand 3 (DLL3)-targeted Therapies in Different Indications 7.3. Clinical Applications of Delta-like Ligand 3 (DLL3)-targeted Therapies 8. Target Patient Pool of Delta-like Ligand 3 (DLL3)-targeted Therapies 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM 8.5. Total Treatable Cases in Selected Indication for Delta-like Ligand 3 (DLL3)-targeted Therapies in the 7MM 9. Marketed Therapies 9.1. Key Competitors 9.2. IMDELLTRA (tarlatamab-dlle): Amgen 9.2.1. Product Description 9.2.2. Regulatory milestones 9.2.3. Other developmental activities 9.2.4. Clinical development 9.2.5. Safety and efficacy List to be continued in the report 10. Emerging Therapies 10.1. Key Competitors 10.2. Peluntamig (PT217): Phanes Therapeutics 10.2.1. Product Description 10.2.2. Other developmental activities 10.2.3. Clinical development 10.2.4. Safety and efficacy 10.3. MK-6070/ HPN328-4001/ DS3280: Merck/ Daiichi Sankyo 10.3.1. Product Description 10.3.2. Other developmental activities 10.3.3. Clinical development 10.3.4. Safety and efficacy List to be continued in the report 11. Delta-like Ligand 3 Targeted Therapies: Seven Major Market Analysis 11.1. Key Findings 11.2. Market Outlook 11.3. Conjoint Analysis 11.4. Key Market Forecast Assumptions 11.4.1. Cost Assumptions and Rebates 11.4.2. Pricing Trends 11.4.3. Analogue Assessment 11.4.4. Launch Year and Therapy Uptakes 11.5. Total Market Sizes of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in the 7MM 11.6. The United States Market Size 11.6.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies in the United States 11.6.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indication in the United States 11.6.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in the United States 11.7. EU4 and the UK 11.7.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies in EU4 and the UK 11.7.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in EU4 and the UK 11.7.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in EU4 and the UK 11.8. Japan 11.8.1. Total Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies Inhibitors in Japan 11.8.2. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Indications in Japan 11.8.3. Market Size of Delta-like Ligand 3 (DLL3)-targeted Therapies by Therapies in Japan 12. SWOT Analysis 13. KOL Views 14. Unmet Needs 15. Market Access and Reimbursement 16. Appendix 16.1. Bibliography 16.2. Report Methodology 17. DelveInsight Capabilities 18. Disclaimer 19. About DelveInsight Related Reports Small Cell Lung Cancer Market Small Cell Lung Cancer Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCLC companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others. Extensive-Stage Small Cell Lung Cancer Market Extensive-Stage Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ES-SCLC companies, including Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC, among others. Neuroendocrine Carcinoma Market Neuroendocrine Carcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NEC companies, including Novartis AG, Boehringer Ingelheim International GmbH, Pfizer, Inc., Ipsen Pharma, AVEO Oncology, Hutchison MediPharma Limited, Progenics Pharmaceuticals, among others. Neuroendocrine Prostate Cancer Market Neuroendocrine Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine prostate cancer companies, including Pfizer, Novartis, Bristol-Myers Squibb, Exelixis, Ipsen, Takeda, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Business Upturn
a day ago
- Health
- Business Upturn
Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai
By Business Wire India Published on June 19, 2025, 15:06 IST Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 on 19th and 20th June in Dubai, United Arab Emirates. It was inaugurated by Prof. Dr. Frank Stangenberg-Haverkamp, Chairman of Merck Foundation Board of Trustees, and Senator, Dr. Rasha Kelej, CEO of Merck Foundation and President of Merck Foundation First Ladies Initiative along with The First Ladies of 14 African and Asian countries, who joined as the Guests of Honor and Keynote Speakers. Senator Dr. Rasha Kelej, CEO of Merck Foundation and President of 'Merck Foundation First Ladies Initiative' emphasized, 'It is my great honor to welcome our esteemed Guests of Honor and Keynote Speakers, The First Ladies of Africa and Asia, and Ambassadors of our 'More Than a Mother' campaign to the 7th Edition of the Merck Foundation First Ladies Initiative – MFFLI Summit. Through this important platform, we have collectively exchanged valuable experiences and engaged in meaningful discussions on the impact of our programs, which are aimed at transforming patient care and raising awareness of a wide range of critical social and health issues.' Prof. Dr. Frank Stangenberg Haverkamp, Chairman of Merck Foundation Board of Trustees, added, 'At Merck Foundation, our goal is improving overall health and well-being by building healthcare capacity and by providing access to quality & equitable healthcare solutions in Africa, Asia and beyond. I would like to sincerely thank our Ambassadors and partners. Together, with your unwavering support and collaboration, we will continue to work towards our vision of a world where everyone can lead a healthy and happy life.' The First Ladies of 14 countries, who are also the Ambassadors of 'Merck Foundation More Than a Mother', joined as Guests of Honor and Keynote Speakers. They are: Senator, Dr. Rasha Kelej stated, 'I am proud to share that Merck Foundation has provided more than 2280 scholarships for young doctors from 52 countries in 44 critical and underserved specialties. Many of our Merck Foundation Alumni are becoming the first specialists in their countries. Together with our Ambassadors and Partners, we are making history and transforming the patient care landscape across Africa and beyond. Many of them are becoming the first specialists in their countries.' 'During our Conference, we also marked together the World Infertility Awareness Month, observed in June, through our signature campaign 'Merck Foundation More Than a Mother', which aims to empower infertile and childless women by providing access to information, education, and change of mindset. I am happy to share that out of the total 2280 scholarships, more than 700 scholarships have been provided for training in Fertility, Embryology, Sexual and Reproductive Medicine, Clinical Psychiatry, Women's Health, Urology, Laparoscopic Surgical Skills, and Family Medicine, to improve access to fertility care and women's health', she further added. During the 7th Edition of Merck Foundation First Ladies Initiative -MFFLI Summit, two important occasions were marked: the 8th Anniversary of Merck Foundation and 13 years of Merck Foundation's development programs that started in 2012. On the first day, the Plenary Session of the Merck Foundation First Ladies Initiative -MFFLI Summit took place, featuring a high-level panel discussion with the participating First Ladies of Africa and Asia. Moreover, a high-level ministerial panel discussion was held with African Ministers and top healthcare experts from across the globe. On Day 2 of the conference, three key parallel sessions will be held: Two medical and scientific sessions covering Oncology and Fertility Topics, and a community awareness session, Merck Foundation Health Media Training. This session will emphasize the critical role of the media in influencing communities and driving cultural change, with regards to a wide range of social and health issues like Breaking Infertility Stigma, Supporting Girls' Education, Stopping GBV, Ending Child Marriage & FGM, Empowering Women, Diabetes and Hypertension Awareness. The conference is being conducted in a hybrid format, enabling over 6,000 audiences from more than 70 countries to benefit, meet and discuss strategies and solutions for the health and social challenges in their countries safely and effectively. Countries participating in the 7th Edition of Merck Foundation First Ladies Initiative: Angola, Bangladesh, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Canada, Central Africa Republic, Cambodia, Chad, Côte d'Ivoire, Republic of the Congo, Democratic Republic of the Congo, Egypt, Ethiopia, France, Gabon, Germany, Ghana, Guinea – Bissau, Guinea – Conakry, India, Indonesia, Kenya, Lesotho, Liberia, Malawi, Malaysia, Maldives, Mali, Mauritania, Mauritius, Mexico, Mozambique, Myanmar, Namibia, Nepal, Niger, Nigeria, Peru, Philippines, Russia, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Sri Lanka, Sudan, Tanzania, Thailand, The Gambia, Togo, Tunisia, U.A.E, UK, Uganda, US, Vietnam, Zambia, Zimbabwe and more. The 7th Edition of Merck Foundation First Ladies Initiative is streamed live on the social media handles of Merck Foundation and Senator, Dr. Rasha Kelej, CEO of Merck Foundation: @Merck Foundation: Facebook, X, Instagram, and YouTube. @Rasha Kelej: Facebook, X, Instagram, and YouTube. Link to the Facebook live stream of Inaugural Session of Merck Foundation First Ladies High Level Panel: Merck Foundation is transforming the Patient care landscape and making history together with their partners in Africa, Asia, and beyond, through: Merck Foundation is also creating a culture shift and breaking the silence about a wide range of social and health issues in Africa and underserved communities through: Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Yahoo
2 days ago
- Business
- Yahoo
Merck (NYSE:MRK) Begins Phase 3 Trial Of Innovative Prostate Cancer Treatment
Merck recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant prostate cancer. Alongside this major development, the company saw FDA approval of KEYTRUDA for head and neck cancer, and embarked on a collaborative Phase 3 dengue vaccine trial, possibly contributing to its 2.92% stock price increase over the last month. In a market characterized by geopolitical tensions and economic anticipations, these announcements may have buoyed Merck as it matches broader market trends. We've spotted 1 weakness for Merck you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. Merck's latest endeavors, including the IDeate-Prostate01 phase 3 trial and the FDA approval of KEYTRUDA for head and neck cancer, are expected to bolster its long-term growth narrative. These developments could enhance Merck's leadership in oncology and potentially strengthen revenue streams, aligning with its broader strategy of introducing over 20 growth drivers with blockbuster potential. Merck's share price saw a 2.92% increase last month, closely reflecting these ongoing advancements. However, it's important to juxtapose this with the analysts' consensus price target of US$105.02, indicating a substantial upside potential of approximately 24.7% from the current share price of US$79.04. Over the last five years, Merck's total shareholder return, including dividends, was 24.36%, showcasing a steady appreciation. In comparison to the broader US market, Merck slightly underperformed over the past year, as it returned 9.8% while the US Pharmaceuticals industry experienced a 9% decline. The recent news could influence revenue forecasts positively if product launches succeed and if the pipeline supports new growth avenues. Additionally, with earnings anticipated to rise from US$17.43 billion today to US$24.6 billion by May 2028, the developments could accelerate earnings growth, assuming no significant market or regulatory disruptions. Evaluate Merck's prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MRK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 days ago
- Health
- Yahoo
American Kidney Fund Launches Kidney Cancer Education Campaign
ROCKVILLE, Md., June 18, 2025 (GLOBE NEWSWIRE) -- Ahead of World Kidney Cancer Day on June 19, the American Kidney Fund (AKF) today announced a new educational campaign on renal (kidney) cancer. With support from Merck, this campaign will provide people with kidney cancer and their families and caregivers easy-to-understand information and support. Kidney cancer accounts for 4% of all cancers, according to the National Cancer Institute (NCI). About 80,000 people are diagnosed with some type of kidney cancer annually, and there were more than 675,000 people living with kidney and renal pelvis cancer in 2022, according to NCI. 'AKF is dedicated to helping people facing any type of kidney issue, including the numerous forms of kidney cancer that can damage these vital organs and spread to other organs,' said AKF President and CEO LaVarne A. Burton. 'We are grateful to Merck for their support in expanding these resources to help thousands of people living with kidney cancer.' As part of the campaign, AKF has developed new educational resources including a Talk-to-Your Doctor downloadable guide and an animated explainer video on kidney cancer. New resources are also available in Spanish. Additionally, AKF has enhanced its existing content on clear and non-clear renal cell carcinoma as well as non-renal cell tumors and other kinds of kidney cancer. The most common type of kidney cancer in adults is renal cell carcinoma (RCC), which is further divided into clear cell renal cell carcinoma (ccRCC) and non-clear cell renal carcinoma (ncRCC). Clear cell renal cell carcinoma (ccRCC) is also known as conventional renal cell carcinoma because it is the most common type of kidney cancer, making up 8 out of 10 cases of adult kidney cancer. Non-clear cell renal carcinoma (nccRCC) is an umbrella term for other kinds of renal cell carcinomas. There are more than 15 types of nccRCC. While doctors do not know what causes kidney cancer, there are some factors that can increase someone's risk of developing it. These include smoking, being overweight, having high blood pressure, having a family history of kidney cancer, having certain inherited or genetic diseases, and long-term treatment for kidney failure. ### About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of 1 in 7 Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy. AKF is one of the nation's top-rated nonprofits, investing 96 cents of every donated dollar in programs, and it has received 24 consecutive 4-Star ratings from Charity Navigator as well as the Platinum Seal of Transparency from Candid, formerly known as GuideStar. For more information, please visit or connect with us on Facebook, Twitter, Instagram and LinkedIn. CONTACT: Nancy Gregory American Kidney Fund (240) 292-7077 ngregory@
